What Do We Know About Smoking Alternatives? A Study on IQOS Tobacco Heaters
DOI:
https://doi.org/10.12775/QS.2024.35.56294Keywords
harm reduction, nicotine dependence, smoking alternatives, heated tobacco products, modified risk tobacco productsAbstract
Introduction
Nicotine addiction poses a significant public health concern in Poland, exacerbated by smoking, e-cigarettes, and heated tobacco products. While tobacco companies claim their alternatives aid cessation, their vested interests warrant cautious scrutiny. This study examines tobacco harm reduction strategies.
Aim of the Study
This study examines IQOS tobacco heaters as a potential harm reduction alternative for smokers. Analyzing health data and regulatory findings, particularly from the FDA, it evaluates the effectiveness and public health impact of heated tobacco products within broader harm reduction strategies.
Materials and Methods
This study examined literature and data to assess IQOS and heated tobacco products' chemical and health risks. It analyzed findings to compare IQOS aerosol and cigarette smoke toxicant exposures, clarifying IQOS's nicotine profile and smoking cessation potential.
Conclusion
The findings indicate IQOS may reduce certain toxin exposures compared to cigarettes, but long-term health impacts are unclear. Further research is needed on IQOS's effects, including disease, addiction, and population-level consequences. Cautious regulation is warranted due to youth risks and ethical concerns surrounding nicotine alternatives.
References
NIZP-PZH. The health situation of the Polish population and its determinants. Warsaw 2022: National Institute of Public Health - National Institute of Hygiene; 2022.
Food and Drug Law Institute, A Model Risk Continuum for Tobacco and Nicotine Products by Chris Proctor, Sudhanshu Patwardhan, and James Murphy https://www.fdli.org/2017/08/spotlight-tobacco-model-risk-continuum-tobacco-nicotine-products/ Access 06.08.2024
Institute of Medicine (US) Committee to Assess the Science Base for Tobacco Harm Reduction. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Stratton K, Shetty P, Wallace R, Bondurant S, editors. Washington (DC): National Academies Press (US); 2001. PMID: 25057541. 10:189–195. doi: 10.1136/tc.10.2.189
Institute of Medicine. Scientific standards for studies on modified risk tobacco products. Washington, DC: National Academies Press; 2012. p. 370], [Murphy J, Gaca M, Lowe F, et al. Assessing modified risk tobacco and nicotine products: description of the scientific framework and assessment of a closed modular electronic cigarette. Regul Toxicol Pharmacol. 2017;90:342–357. doi: 10.1016/j.yrtph.2017.09.008
http://www.skaids.org/prep Access 06.08.2024
Heat-not-burn tobacco products: a systematic literature review. Erikas Simonavicius, Ann McNeill,Lion Shahab and Leonie S Brose. Tob Control. 2019 Sep; 28(5): 582–594. Published online 2018 Sep 4. doi: 10.1136/tobaccocontrol-2018-054419.
Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act | FDA (Opublikowane w Kwietniu 2012). Access 06.08.2024
https://www.fda.gov/tobacco-products/products-ingredients-components/harmful-and-potentially-harmful-constituents-hphcs#Preliminary%20HPHC%20List Access 06.08.2024
McNeill, Ann, and Marcus R. Munafò. “Reducing harm from tobacco use.” Journal of Psychopharmacology 27.1 (2013): 13-18.
US FDA, FDA News Release, FDA announces comprehensive regulatory plan to shift trajectory of tobacco-related disease, death, July 27 (2017).
McNeill, A., & Munafò, M. R. (2012). Reducing harm from tobacco use. Journal of Psychopharmacology, 27(1), 13–18. doi:10.1177/0269881112458731
Tobacco Advisory Group of the Royal College of Physicians “Harm reduction in nicotine addiction Helping people who can’t quit.” Royal College of Physicians (2007).
https://www.fda.gov/tobacco-products/advertising-and-promotion/fda-authorizes-modified-risk-tobacco-products FDA Decision on Snus Products Issued 22.10.2019; Access 06.08.2024
Foulds, Jonathan, et al. “Effect of smokeless tobacco (snus) on smoking and public health in Sweden.” Tobacco control 12.4 (2003): 349-359.
https://www.fdli.org/2017/08/spotlight-tobacco-model-risk-continuum-tobacco-nicotine-products/
Charlotta Pisinger, Elif Dagli, Filippos T. Filippidis, Linnea Hedman, Christer Janson, Stelios Loukides, Sofia Ravara, Isabel Saraiva, Jørgen Vestbo Komitet Kontroli Tytoniu ERS, w imieniu ERS. European Respiratory Journal 2019 54: 1902009; DOI: 10.1183/13993003.02009-2019.
Drope J, Schluger N. The Tobacco Atlas. 6th Edn. Georgia, American Cancer Society, 2018. www.cancer.org/latest-news/twelve-key-findings-from-the-new-edition-of-the-tobacco-atlas.html. Access 06.08.2024
Thyrian JR, Panagiotakos DB, Polychronopoulos E, et al. The relationship between smokers’ motivation to quit and intensity of tobacco control at the population level: a comparison of five European countries. BMC Public Health 2008; 8: 2
Orleans CT, Schoenbach VJ, Salmon MA, et al. A survey of smoking and quitting patterns among black Americans. Am J Public Health 1989; 79: 176–181.
Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013; 5: CD009329.
Tonnesen P, Mikkelsen K, Bremann L. Smoking cessation with smokeless tobacco and group therapy: an open, randomized, controlled trial. Nicotine Tob Res 2008; 10: 1365–1372.
Hatsukami DK, Severson H, Anderson A, et al. Randomised clinical trial of snus versus medicinal nicotine among smokers interested in product switching. Tob Control 2016; 25: 267–274
Hajek P, Phillips-Waller A, Przulj D, et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. N Engl J Med 2019; 380: 629–637.
Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med 2016; 4: 116–128.
Hedman L, Backman H, Stridsman C, et al. Association of electronic cigarette use with smoking habits, demographic factors, and respiratory symptoms. JAMA Netw Open 2018; 1: e180789.
Sung HY, Wang Y, Yao T, et al. Polytobacco use and nicotine dependence symptoms among US adults, 2012– 2014. Nicotine Tob Res 2018; 20: Suppl. 1, S88–S98.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Review of the Health Effects of Electronic Nicotine Delivery Systems. Stratton K, Kwan L, Eaton D, eds. Public Health Consequences of E-Cigarettes. Washington, National Academies Press (US), 2018.
Kennedy CD, van Schalkwyk MCI, McKee M, et al. The cardiovascular effects of electronic cigarettes: a systematic review of experimental studies. Prev Med 2019; 127: 105770.
Chen L, Ge Q, Tjin G, et al. Effects of cigarette smoke extract on human airway smooth muscle cells in COPD. Eur Respir J 2014; 44: 634–646
Sohal S, Eapen M, Naidu V, et al. IQOS exposure impairs human airway cell homeostasis: direct comparison with traditional cigarette and e-cigarette. ERJ Open Res 2019; 5: 00159-2018.
Garcia-Arcos I, Geraghty P, Baumlin N, et al. Chronic electronic cigarette exposure in mice induces features of COPD in a nicotine-dependent manner. Thorax 2016; 71: 1119–1129.
Staudt MR, Salit J, Kaner RJ, et al. Altered lung biology of healthy never smokers following acute inhalation of E-cigarettes. Respir Res 2018; 19: 78
Glantz SA. PMI’s own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes. Tob Control 2018; 27: Suppl. 1, S9–S12
Sohal S, Eapen M, Naidu V, et al. IQOS exposure impairs human airway cell homeostasis: direct comparison with traditional cigarette and e-cigarette. ERJ Open Res 2019; 5: 00159-2018
Dutra LM, Glantz SA. E-cigarettes and national adolescent cigarette use: 2004–2014. Pediatrics 2017; 139: e20162450
Dai H, Leventhal AM. Prevalence of e-cigarette use among adults in the United States, 2014–2018. JAMA 2019; in press [https://doi.org/10.1001/jama.2019.15331].
Filippidis FT, Laverty AA, Gerovasili V, et al. Two-year trends and predictors of e-cigarette use in 27 European Union member states. Tob Control 2017; 26: 98–104
Soneji S, Barrington-Trimis JL, Wills TA, et al. Association between initial use of e-cigarettes and subsequent cigarette smoking among adolescents and young adults: a systematic review and meta-analysis. JAMA Pediatr 2017; 171: 788–797
https://www.gov.pl/web/gis/polska-krajem-wolnym-od-tytoniu-2030 Access 28.09.2024)
https://www.fda.gov/tobacco-products/advertising-and-promotion/fda-authorizes-modified-risk-tobacco-products#Ref Access 06.08.2024
https://www.fda.gov/tobacco-products/health-effects-tobacco-use/health-fraud Access 06.08.2024
Family Smoking Prevention and Tobacco Control Act (Fsptca, Pub. L. 111-31, 21 U.S.C. 387 Et Seq), 2009.
Food and Drug Administration. TPSAC meeting materials and Information, 2018
The U.S. Food and Drug Administration. FDA authorizes marketing of IQOS Tobacco heating system with ‘reduced exposure’ information, 2020. Available: https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-iqos-tobacco-heating-system-reduced-exposure-information
The U.S. Congress. Family Smoking and Prevention Tobacco Control Act. 21 U.S.C. § 387p(a)(2), (B) (2013) 2009
https://www.fda.gov/media/139797/download IQOS Report Access 06.08.204
McKelvey K, Baiocchi M, Halpern-Felsher B Pmi’s heated tobacco products marketing claims of reduced risk and reduced exposure may entice youth to try and continue using these products. Tob Control 2020;29:e18–24. doi: 10.1136/tobaccocontrol-2019-055318
https://apps.who.int/iris/bitstream/handle/10665/343287/9789240032095-eng.pdf?sequence=1&isAllowed=y Raport MPOWER
The ERS Tobacco Control Committee. ERS Position Paper on Tobacco Harm Reduction https://www.ersnet.org/news-and-features/news/ers-position-paper-on-tobacco-harm-reduction-2/ Access 06.08.2024
World Health Organization. WHO Framework Convention on Tobacco Control.Articles (who.int) Access 06.08.2024
Surgeon General’s Report: The Health Consequences of Smoking – 50 Years of Progress. Rockville, US Department of Health, Human Services, 2014.
Eckford R, Severini G, Sebrié EM, Muggli ME, Beem A, Rosen D, Crosbie E. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS®: implications for regulation in Latin America. Rev Panam Salud Publica. 2022 Oct 10;46:e155. doi: 10.26633/RPSP.2022.155. PMID: 36245905; PMCID: PMC9553011
Berg CJ, Duan Z, Wang Y, et al. Impact of FDA endorsement and modified risk versus exposure messaging in IQOS ads: a randomised factorial experiment among US and Israeli adults Tobacco Control Published Online First: 25 November 2022. doi: 10.1136/tc-2022-057639
McKelvey K, Baiocchi M, Halpern-Felsher B; PMI’s heated tobacco products marketing claims of reduced risk and reduced exposure may entice youth to try and continue using these products Tobacco Control 2020;29:e18-e24
Ardati O, Adeniji A, El Hage R, et al. Impact of smoking intensity and device cleaning on IQOS emissions: comparison with an array of cigarettes Tobacco Control Published Online First: 06 January 2023. doi: 10.1136/tc-2022-057802
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Filip Nadolny, Jędrzej Jabłoński, Martyna Kania, Agnieszka Adamowska, Alicja Śniatała, Hanna Bartkowiak, Damian Grubski, Kacper Ziarnik
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 211
Number of citations: 0
